BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 36463238)

  • 1. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
    Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.
    Rae S; Spillane C; Blackshields G; Madden SF; Keenan J; Stordal B
    Hum Cell; 2022 Sep; 35(5):1547-1559. PubMed ID: 35794446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
    Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
    Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells.
    Aptecar L; Puech C; Lopez-Crapez E; Peter M; Coopman P; D'Hondt V; Freiss G
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
    Wang Z; Yang L; Su X; Wu X; Su R
    J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
    Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
    Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes as mediators of platinum resistance in ovarian cancer.
    Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
    Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
    Qiu PY; Deng XH; Li L
    Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
    Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
    Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
    Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
    Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.
    Yang J; Xing H; Lu D; Wang J; Li B; Tang J; Gu F; Hong L
    J Cell Mol Med; 2019 Jun; 23(6):4005-4018. PubMed ID: 30993885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.
    Haslehurst AM; Koti M; Dharsee M; Nuin P; Evans K; Geraci J; Childs T; Chen J; Li J; Weberpals J; Davey S; Squire J; Park PC; Feilotter H
    BMC Cancer; 2012 Mar; 12():91. PubMed ID: 22429801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of exosomes secreted during the epithelial-mesenchymal transition and potential biomarkers of mesenchymal high-grade serous ovarian carcinoma.
    Ferreira GA; Thomé CH; Izumi C; Grassi ML; Lanfredi GP; Smolka M; Faça VM; Candido Dos Reis FJ
    J Ovarian Res; 2023 Nov; 16(1):232. PubMed ID: 38031074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.
    Pan JX; Qu F; Wang FF; Xu J; Mu LS; Ye LY; Li JJ
    Arch Gynecol Obstet; 2017 Dec; 296(6):1145-1152. PubMed ID: 28975405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.